Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
27 août 2019 08h00 HE
|
Adaptimmune Therapeutics plc; Noile-Immune Biotech, Inc.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech,...